A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

• Drug: Bapineuzumab 0.5 mg/kg
  
  Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
  Other Name: AAB-001
• Drug: Bapineuzumab 1.0 m/kg
  
  I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
  Other Name: AAB-001

• Experimental: Bapineuzumab 0.5 mg/kg
  
  bapineuzumab
  Intervention: Drug: Bapineuzumab 0.5 mg/kg
• Experimental: Bapineuzumab 1.0 m/kg
  
  bapineuzumab
  Intervention: Drug: Bapineuzumab 1.0 m/kg

Inclusion Criteria:

• Subject has completed study 3133K1-3000 and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease
• Mini-Mental Status Examination (MMSE) >=10 at screening
• Caregiver able to attend all clinic visits with subject

Exclusion Criteria:

• Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.
• Any significant brain MRI abnormality.
• Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening